Addition Of A Mast Cell Stabilizing Compound To Organ Preservation Solutions Decreases Lung Reperfusion Injury

Abstract

Objective: Research in lung transplant preservation has generally focused on free radicals and enzyme release from neutrophils, parenchymal cells, macrophages, and endothelium. The lung has a large resident population of mast cells that, when activated, release potent inflammatory mediators. We hypothesized that adding an inhibitor of mast cell degranulation, lodoxamide tromethamine (10 μmol/L), to Euro-Collins and University of Wisconsin preservation solutions, would decrease lung preservation injury. Methods: Rat lungs were isolated, flushed with the respective solution, and stored at 4° C for 6 or 12 hours. The lungs were reperfused with fresh blood and ventilated with 100% oxygen. Alveolar-arterial oxygen difference, oxygen tension, capillary filtration coefficient, and compliance were determined. Results: After 6 hours of ischemic storage: lodoxamide tromethamine–enhanced Euro-Collins solution decreased alveolar-arterial oxygen difference from 539 to 457 ( p = 0.004), increased oxygen tension from 119 to 205 mm Hg ( p = 0.006), and decreased capillary filtration coefficient from 3.9 to 2.0 ( p < 0.001); lodoxamide tromethamine–enhanced University of Wisconsin solution decreased alveolar-arterial oxygen difference from 546 to 317 ( p < 0.001), increased oxygen tension from 166 to 335 mm Hg ( p < 0.001), and decreased capillary filtration coefficient from 3.0 to 1.7 ( p < 0.001). After 12 hours of ischemic storage, lodoxamide tromethamine–enhanced Euro-Collins solution decreased alveolar-arterial oxygen difference from 588 to 485 ( p < 0.001), increased oxygen tension from 100 to 161 mm Hg ( p = 0.012), decreased capillary filtration coefficient from 6.2 to 2.6 ( p < 0.001), and increased compliance from 0.12 to 0.21 ( p < 0.001); lodoxamide tromethamine–enhanced University of Wisconsin solution decreased alveolar-arterial oxygen difference from 478 to 322 ( p < 0.001), increased oxygen tension from 214 to 335 mm Hg ( p < 0.001), decreased capillary filtration constant from 4.2 to 2.0 ( p < 0.001), and increased compliance from 0.20 to 0.25 ( p < 0.001). Conclusions: Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance. These results are relevant as Euro-Collins and University of Wisconsin solutions are the most common clinically used lung preservation solutions. This study also highlights the deleterious role of resident mast cells in preservation injury. (J Thorac Cardiovasc Surg 1998;115:631-7)